Wim Dokter
Chief Scientific Officer Byondis B.V.
Wim was appointed Chief Scientific Officer of Byondis in 2019. He brings more than 25 years of pharmaceutical and biotechnology experience, leading international and multidisciplinary teams in drug development programs, including the delivery of several clinical drug candidates in oncology, autoimmunity and diabetes.
Before being appointed to the Byondis leadership team, Wim was Executive Vice President, Preclinical, at Synthon Biopharmaceuticals. Prior to this, he was Director of Pharmacology and Immunology Program Leader at Schering-Plough, which merged with Merck & Co. (MSD). Before this, he began his R&D career in a progression of roles with broader responsibility at Organon.
A scientist and researcher, Wim has co-authored 50-plus peer-reviewed articles in scientific journals. He holds an MSc in (Bio)Chemistry and a PhD (cum laude) in Hematology and Oncology from the University of Groningen, the Netherlands.
Seminars
- Demonstrating rationale to develop conditionally active ADCs to overcome challenges with target-mediated toxicity and improve therapeutic index
- Laying out ADC masking mechanism leveraging steric masking nanobody-peptide activated by a variety of proteases in the tumor
- Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles
- Presenting development of a novel antifolate linker-payload platform, leveraging a toxin class with a clinically validated mechanism of action
- Exploring in vitro and in vivo preclinical development and physicochemical properties of frontrunner antifolate ADC program
- Laying out pharmacology studies and dose range finding investigation in the lead up to antifolate ADC IND studies
